Literature DB >> 33584712

Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals.

Savannah E Butler1, Andrew R Crowley1, Harini Natarajan1, Shiwei Xu2, Joshua A Weiner3, Carly A Bobak2, Daniel E Mattox4, Jiwon Lee3, Wendy Wieland-Alter5, Ruth I Connor5, Peter F Wright5, Margaret E Ackerman1,2,3.   

Abstract

Understanding humoral immune responses to SARS-CoV-2 infection will play a critical role in the development of vaccines and antibody-based interventions. We report systemic and mucosal antibody responses in convalescent individuals who experienced varying severity of disease. Whereas assessment of neutralization and antibody-mediated effector functions revealed polyfunctional antibody responses in serum, only robust neutralization and phagocytosis were apparent in nasal wash samples. Serum neutralization and effector functions correlated with systemic SARS-CoV-2-specific IgG response magnitude, while mucosal neutralization was associated with nasal SARS-CoV-2-specific IgA. Antibody depletion experiments support the mechanistic relevance of these correlations. Associations between nasal IgA responses, virus neutralization at the mucosa, and less severe disease suggest the importance of assessing mucosal immunity in larger natural infection cohorts. Further characterization of antibody responses at the portal of entry may define their ability to contribute to protection from infection or reduced risk of hospitalization, informing public health assessment strategies and vaccine development efforts.
Copyright © 2021 Butler, Crowley, Natarajan, Xu, Weiner, Bobak, Mattox, Lee, Wieland-Alter, Connor, Wright and Ackerman.

Entities:  

Keywords:  COVID-19; IgA; IgG; SARS-CoV-2; antibody; mucosal immunity; neutralization; systems serology

Mesh:

Substances:

Year:  2021        PMID: 33584712      PMCID: PMC7876222          DOI: 10.3389/fimmu.2020.618685

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  84 in total

1.  Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection.

Authors:  K A Callow
Journal:  J Hyg (Lond)       Date:  1985-08

2.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.

Authors:  Nina Le Bert; Anthony T Tan; Kamini Kunasegaran; Christine Y L Tham; Morteza Hafezi; Adeline Chia; Melissa Hui Yen Chng; Meiyin Lin; Nicole Tan; Martin Linster; Wan Ni Chia; Mark I-Cheng Chen; Lin-Fa Wang; Eng Eong Ooi; Shirin Kalimuddin; Paul Anantharajah Tambyah; Jenny Guek-Hong Low; Yee-Joo Tan; Antonio Bertoletti
Journal:  Nature       Date:  2020-07-15       Impact factor: 49.962

3.  Highly parallel characterization of IgG Fc binding interactions.

Authors:  Austin W Boesch; Eric P Brown; Hao D Cheng; Maame Ofua Ofori; Erica Normandin; Peter A Nigrovic; Galit Alter; Margaret E Ackerman
Journal:  MAbs       Date:  2014 Jul-Aug       Impact factor: 5.857

4.  A perspective on potential antibody-dependent enhancement of SARS-CoV-2.

Authors:  Ann M Arvin; Katja Fink; Michael A Schmid; Andrea Cathcart; Roberto Spreafico; Colin Havenar-Daughton; Antonio Lanzavecchia; Davide Corti; Herbert W Virgin
Journal:  Nature       Date:  2020-07-13       Impact factor: 49.962

5.  Development of nasal, fecal and serum isotype-specific antibodies in calves challenged with bovine coronavirus or rotavirus.

Authors:  L J Saif
Journal:  Vet Immunol Immunopathol       Date:  1987-12       Impact factor: 2.046

6.  Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.

Authors:  Yunlong Cao; Bin Su; Xianghua Guo; Wenjie Sun; Yongqiang Deng; Linlin Bao; Qinyu Zhu; Xu Zhang; Yinghui Zheng; Chenyang Geng; Xiaoran Chai; Runsheng He; Xiaofeng Li; Qi Lv; Hua Zhu; Wei Deng; Yanfeng Xu; Yanjun Wang; Luxin Qiao; Yafang Tan; Liyang Song; Guopeng Wang; Xiaoxia Du; Ning Gao; Jiangning Liu; Junyu Xiao; Xiao-Dong Su; Zongmin Du; Yingmei Feng; Chuan Qin; Chengfeng Qin; Ronghua Jin; X Sunney Xie
Journal:  Cell       Date:  2020-05-18       Impact factor: 41.582

7.  Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters.

Authors:  Lisa H Tostanoski; Frank Wegmann; Amanda J Martinot; Carolin Loos; Katherine McMahan; Noe B Mercado; Jingyou Yu; Chi N Chan; Stephen Bondoc; Carly E Starke; Michael Nekorchuk; Kathleen Busman-Sahay; Cesar Piedra-Mora; Linda M Wrijil; Sarah Ducat; Jerome Custers; Caroline Atyeo; Stephanie Fischinger; John S Burke; Jared Feldman; Blake M Hauser; Timothy M Caradonna; Esther A Bondzie; Gabriel Dagotto; Makda S Gebre; Catherine Jacob-Dolan; Zijin Lin; Shant H Mahrokhian; Felix Nampanya; Ramya Nityanandam; Laurent Pessaint; Maciel Porto; Vaneesha Ali; Dalia Benetiene; Komlan Tevi; Hanne Andersen; Mark G Lewis; Aaron G Schmidt; Douglas A Lauffenburger; Galit Alter; Jacob D Estes; Hanneke Schuitemaker; Roland Zahn; Dan H Barouch
Journal:  Nat Med       Date:  2020-09-03       Impact factor: 53.440

8.  Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus.

Authors:  C M Chan; Herman Tse; S S Y Wong; P C Y Woo; S K P Lau; L Chen; B J Zheng; J D Huang; K Y Yuen
Journal:  J Clin Virol       Date:  2009-04-01       Impact factor: 3.168

9.  Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.

Authors:  Juanjuan Zhao; Quan Yuan; Haiyan Wang; Wei Liu; Xuejiao Liao; Yingying Su; Xin Wang; Jing Yuan; Tingdong Li; Jinxiu Li; Shen Qian; Congming Hong; Fuxiang Wang; Yingxia Liu; Zhaoqin Wang; Qing He; Zhiyong Li; Bin He; Tianying Zhang; Yang Fu; Shengxiang Ge; Lei Liu; Jun Zhang; Ningshao Xia; Zheng Zhang
Journal:  Clin Infect Dis       Date:  2020-11-19       Impact factor: 9.079

10.  Broad neutralization of SARS-related viruses by human monoclonal antibodies.

Authors:  Anna Z Wec; Daniel Wrapp; Andrew S Herbert; Daniel P Maurer; Denise Haslwanter; Mrunal Sakharkar; Rohit K Jangra; M Eugenia Dieterle; Asparouh Lilov; Deli Huang; Longping V Tse; Nicole V Johnson; Ching-Lin Hsieh; Nianshuang Wang; Juergen H Nett; Elizabeth Champney; Irina Burnina; Michael Brown; Shu Lin; Melanie Sinclair; Carl Johnson; Sarat Pudi; Robert Bortz; Ariel S Wirchnianski; Ethan Laudermilch; Catalina Florez; J Maximilian Fels; Cecilia M O'Brien; Barney S Graham; David Nemazee; Dennis R Burton; Ralph S Baric; James E Voss; Kartik Chandran; John M Dye; Jason S McLellan; Laura M Walker
Journal:  Science       Date:  2020-06-15       Impact factor: 47.728

View more
  41 in total

Review 1.  Innate and Adaptive Immune Responses in the Upper Respiratory Tract and the Infectivity of SARS-CoV-2.

Authors:  Ranjan Ramasamy
Journal:  Viruses       Date:  2022-04-29       Impact factor: 5.818

2.  Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities.

Authors:  Yaozong Chen; Lulu Sun; Irfan Ullah; Guillaume Beaudoin-Bussières; Sai Priya Anand; Andrew P Hederman; William D Tolbert; Rebekah Sherburn; Dung N Nguyen; Lorie Marchitto; Shilei Ding; Di Wu; Yuhong Luo; Suneetha Gottumukkala; Sean Moran; Priti Kumar; Grzegorz Piszczek; Walther Mothes; Margaret E Ackerman; Andrés Finzi; Pradeep D Uchil; Frank J Gonzalez; Marzena Pazgier
Journal:  Sci Adv       Date:  2022-07-13       Impact factor: 14.957

3.  Decay of Fc-dependent antibody functions after mild to moderate COVID-19.

Authors:  Wen Shi Lee; Kevin John Selva; Samantha K Davis; Bruce D Wines; Arnold Reynaldi; Robyn Esterbauer; Hannah G Kelly; Ebene R Haycroft; Hyon-Xhi Tan; Jennifer A Juno; Adam K Wheatley; P Mark Hogarth; Deborah Cromer; Miles P Davenport; Amy W Chung; Stephen J Kent
Journal:  Cell Rep Med       Date:  2021-05-09

4.  Prolonged evolution of the human B cell response to SARS-CoV-2 infection.

Authors:  Mrunal Sakharkar; C Garrett Rappazzo; Wendy F Wieland-Alter; Ching-Lin Hsieh; Daniel Wrapp; Emma S Esterman; Chengzi I Kaku; Anna Z Wec; James C Geoghegan; Jason S McLellan; Ruth I Connor; Peter F Wright; Laura M Walker
Journal:  Sci Immunol       Date:  2021-02-23

Review 5.  Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?

Authors:  Mattia Tiboni; Luca Casettari; Lisbeth Illum
Journal:  Int J Pharm       Date:  2021-05-06       Impact factor: 6.510

Review 6.  Know your enemy or find your friend?-Induction of IgA at mucosal surfaces.

Authors:  Mats Bemark; Davide Angeletti
Journal:  Immunol Rev       Date:  2021-07-30       Impact factor: 10.983

7.  Beyond neutralization for BNT162b2 mRNA vaccination.

Authors:  Payal Damani-Yokota; Stephen T Yeung; Kamal M Khanna
Journal:  Cell Host Microbe       Date:  2021-07-14       Impact factor: 31.316

8.  Reinfection with SARS-CoV-2 in solid-organ transplant recipients: Incidence density and convalescent immunity prior to reinfection.

Authors:  Stephen Morris; Shweta Anjan; Suresh Pallikkuth; Paola Frattaroli; Steve Courel; Anmary Fernandez; Akina Natori; Lilian Abbo; Savita Pahwa; Giselle Guerra; Yoichiro Natori
Journal:  Transpl Infect Dis       Date:  2022-04-06

Review 9.  Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.

Authors:  Vivek P Chavda; Lalitkumar K Vora; Anjali K Pandya; Vandana B Patravale
Journal:  Drug Discov Today       Date:  2021-07-29       Impact factor: 7.851

Review 10.  Antibody and B cell responses to SARS-CoV-2 infection and vaccination.

Authors:  Katharina Röltgen; Scott D Boyd
Journal:  Cell Host Microbe       Date:  2021-06-17       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.